A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| VU 29 | VU 29 is a potent positive allosteric potentiator at the rat mGlu5 receptor (EC50 = 9 nM) with selectivity for mGlu5 over mGlu1 and mGlu2 receptors (EC50 = 557 nM and 1.51 μM for mGlu1 and mGlu2, respectively). VU 29 binds to the MPEP allosteric site (Ki app = 244 nM). VU 29 was shown to potentiate both DHPG-induced LTP and threshold θ-burst stimulation (TBS)-induced LTP in rat hippocampal slices. Synonyms: N-(1,3-Diphenyl-1H-pyrazolo-5-yl)-4-nitrobenzamide; DPAP; VU-29; VU 29; VU29; 4-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide. Grades: ≥99% by HPLC. CAS No. 890764-36-0. Molecular formula: C22H16N4O3. Mole weight: 384.39. |  |
| VU 29 | VU 29. Group: Biochemicals. Grades: Purified. CAS No. 890764-36-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| VU-29 | VU-29 is a positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor ( EC 50 =9 nM and K i =244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC 50 : rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM) [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 890764-36-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107508. |  |
| VU590 | VU590 is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC 50 of 290 nM. VU590 also inhibits Kir7.1 , with an IC 50 of 8 μM. VU590 is not a good probe of ROMK function in the kidney [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 313505-85-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108595. | |
| VU 590 dihydrochloride | VU 590 dihydrochloride is a selective renal outer medullary potassium channel (Kir1.1, ROMK) inhibitor (IC50 = 294 nM). VU 590 displays no effect upon Kir2.1 or Kir4.1. It also inhibits the inward retifying K+ channel Kir7.1. Synonyms: VU590 HCl; VU590 dihydrochloride; VU590; VU-590; VU 590; CID-4536383; CID 4536383; CID4536383; ML 111; ML111 ; ML-111; 7,13-Bis[(4-nitrophenyl)methyl]-1,4,10-trioxa-7,13-diazacyclopentadecane dihydrochloride. Grades: ≥97% by HPLC. CAS No. 1783987-83-6. Molecular formula: C24H32N4O7.2HCl. Mole weight: 561.46. | |
| VU 590 dihydrochloride | VU 590 dihydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 313505-85-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VU 591 hydrochloride | VU 591 hydrochloride is a selective renal outer medullary potassium channel (Kir1.1, ROMK) antagonist (IC50 = 300 nM). VU 591 exhibits no effect on Kir7.1 at concentrations up to 10 μM and no inhibition of Kir2.1, Kir2.3 or Kir4.1. Synonyms: VU 591 hydrochloride; VU591 hydrochloride; VU-591 hydrochloride; 6-Nitro-2-[(6-nitro-1H-benzimidazol-2-yl)methoxymethyl]-1H-benzimidazole hydrochloride. Grades: ≥99% by HPLC. CAS No. 1315380-70-1. Molecular formula: C16H12N6O5.HCl. Mole weight: 404.76. | |
| VU 591 hydrochloride | VU 591 hydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 1315380-70-1. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VU6001221 | VU6001221 is a choline transporter (CHT) inhibitor (IC50 value of 270 nM) with comparable potency for choline uptake inhibition as ML352, as well as improved PK and CNS penetration. For the first time, VU6001221 allowed evaluation of a CHT inhibitor in a standard preclinical rodent cognition model, namely novel object recognition (NOR). Synonyms: VU 6001221; VU-6001221. Grades: 98%. CAS No. 2002495-17-0. Molecular formula: C20H26ClN3O3. Mole weight: 391.89. | |
| VU 6008667 | VU 6008667 is a selective negative allosteric modulator (NAM) of M5 muscarinic acetylcholine receptor (mAChR) (IC50 values of 1.2 and 1.6 μM in human and rat M5, respectively). Moreover, VU6008667 has high CNS penetration and exhibits a desired short half-life in rats (t1/2 = 2.3 h) for addiction studies. Synonyms: VU 6008667; VU6008667; VU-6008667. Grades: 99%. CAS No. 2092923-21-0. Molecular formula: C24H17ClF2N2O2. Mole weight: 438.85. | |
| VU6036720 | VU6036720 is a potent and specific in vitro inhibitor of Kir4.1/5.1. VU6036720 can inhibit Kir4.1/5.1 channels with an IC 50 value of 0.24 μM. VU6036720 can be used for the research of brain and kidney [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 3026597-12-3. Pack Sizes: 5 mg; 10 mg. Product ID: HY-148304. | |
| Vudalimab | Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 2329669-72-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99166. | |
| Vudalimab | Vudalimab is a humanized bispecific monoclonal antibody targeting both PD-1 and CTLA-4. Vudalimab inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. CAS No. 2329669-72-7. | |
| VUF10166 | VUF10166 is a potent and high-affinity 5-HT 3 receptor antagonist, with K i values of 0.04 nM (5-HT 3 A) and 22 nM (5-HT 3 AB). VUF10166 inhibits 5-HT-induced responses at 5-HT 3 A and 5-HT 3 AB receptors at nanomolar concentrations. At 5-HT 3 receptor , VUF10166 at higher concentrations also acts as a partial agonist, with an EC 50 of 5.2 μM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 155584-74-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100552. | |
| VUF 10166 | VUF 10166. Group: Biochemicals. Grades: Purified. CAS No. 155584-74-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VUF 10166 | VUF 10166 is a potent and competitive 5-HT3 receptor antagonist (IC50 = 0.04 and 22 nM for human 5HT3A and 5-HT3AB receptors, respectively). VUF 10166 exhibits partial agonist activity at 5-HT3A receptors at higher concentrations (EC50 = 5.2 μM). It also acts as a histamine H4 receptor antagonist (pKi = 6.64 in HEK cells). Synonyms: VUF 10166; VUF10166; VUF-10166; 2-Chloro-3-(4-methyl-1-piperazinyl)quinoxaline. Grades: ≥98% by HPLC. CAS No. 155584-74-0. Molecular formula: C13H15ClN4. Mole weight: 262.74. | |
| VUF10460 | VUF10460 is a specific non-imidazole histamine H4 receptor agonist (pKi = 7.46, 8.22 for rat H4 receptor and human H4 receptor respectively) with 50-fold selectivity over the H3 subtype (pKi = 5.75). Synonyms: VUF10460; VUF 10460; VUF-10460; 4-(4-methylpiperazin-1-yl)-6-phenylpyrimidin-2-amine. CAS No. 1028327-66-3. Molecular formula: C15H19N5. Mole weight: 269.34. | |
| VUF 10460 | VUF 10460. Group: Biochemicals. Grades: Purified. CAS No. 1028327-66-3. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VUF 11207 fumarate | VUF 11207 fumarate is a potent ACKR3 (CXCR7) agonist. Synonyms: VUF 11207 fumarate; VUF11207 fumarate; VUF-11207 fumarate; N-[(2E)-3-(2-Fluorophenyl)-2-methyl-2-propen-1-yl]-3,4,5-trimethoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]benzamide fumarate. CAS No. 1785665-61-3. Molecular formula: C27H35FN2O4.C4H4O4. Mole weight: 586.65. | |
| VUF 11207 fumarate | VUF 11207 fumarate. Group: Biochemicals. Grades: Purified. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VUF 11207 trifluoroacetate salt | VUF 11207 is a potent agonist of the G protein-coupled chemokine receptor 7 (CXCR7). It also reduces CXCR7 cell surface expression (EC50 = 14.1 nM) in vitro. Synonyms: VUF11207 TFA salt. Grades: ≥95%. Molecular formula: C27H35FN2O4·CF3COOH. Mole weight: 584.6. | |
| VUF 11222 | VUF 11222 is a high affinity non-peptide CXCR3 agonist (pKi = 7.2). Synonyms: VUF-11222, VUF 11222, VUF11222; 2'-Bromo-N-[[(1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl]-N,N-dimethyl-[1,1'-biphenyl]-4-methanaminium iodide. CAS No. 1414376-84-3. Molecular formula: C25H31BrIN. Mole weight: 552.33. | |
| VUF 5574 | VUF 5574. Group: Biochemicals. Grades: Purified. CAS No. 280570-45-8. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VUF 5574 | VUF 5574 is a potent and competitive antagonist for the human adenosine A3 receptor (Ki = 4 nM) that displays ≥ 2500-fold selectivity over A1 and A2A receptors. Synonyms: VUF5574, VUF 5574, VUF-5574; N-(2-Methoxyphenyl)-N'-[2-(3-pyrindinyl)-4-quinazolinyl]-urea; 1-(2-Methoxyphenyl)-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea. Grades: ≥98% by HPLC. CAS No. 280570-45-8. Molecular formula: C21H17N5O2. Mole weight: 371.39. | |
| VUF 5681 dihydrobromide | VUF 5681 dihydrobromide is a potent histamine H3 receptor silent antagonist (pKi = 8.35). Synonyms: VUF 5681 dihydrobromide; VUF5681 dihydrobromide; VUF-5681 dihydrobromide; 4-[3-(1H-Imidazol-4-yl)propyl]piperidine dihydrobromide. Grades: ≥98% by HPLC. CAS No. 639089-06-8. Molecular formula: C11H19N3.2HBr. Mole weight: 355.11. | |
| VUF 5681 dihydrobromide | VUF 5681 dihydrobromide. Group: Biochemicals. Grades: Purified. CAS No. 639089-06-8. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VUF 8430 dihydrobromide | VUF 8430 dihydrobromide is a high affinity (pKi = 7.5) and potent histamine H4 receptor full agonist (pEC50 = 7.3). VUF 8430 also has moderate affinity for H3 receptors (pKi = 6.0) and weak partial agonist activity at H2 receptors. Synonyms: VUF8430 dihydrobromide; VUF-8430 dihydrobromide; VUF 8430 dihydrobromide; 2-[(Aminoiminomethyl)amino]ethyl carbamimidothioic acid ester dihydrobromide; S-(2-guanidylethyl)-isothiourea; S,2-Guanidinoethylisothiuronium bromide hydrobromide. CAS No. 100130-32-3. Molecular formula: C4H11N5S.2HBr. Mole weight: 323.05. | |
| VUF 8430 dihydrobromide | VUF 8430 dihydrobromide. Group: Biochemicals. Grades: Purified. CAS No. 100130-32-3. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VUF 8430 dihydrobromide | VUF 8430 (dihydrobromide) is a potent and selective histamine H4 receptor agonist with a K i of 31.6 nM and an EC 50 of 50 nM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 100130-32-3. Pack Sizes: 5 mg; 10 mg. Product ID: HY-107555. | |
| vulcanization agents | vulcanization agents. Group: Polymers. |  |
| VULM 1457 | VULM 1457. Group: Biochemicals. Grades: Purified. CAS No. 228544-65-8. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| VULM 1457 | VULM 1457 is an Acyl-CoA that acts as a cholesterol acyltransferase (ACAT) inhibitor. VULM 1457 has been shown to reduce cholesterol levels in the plasma and liver of diabetic-hypercholesterolemic rats. Synonyms: VULM 1457; VULM1457; VULM-1457; N-[2,6-bis(1-Methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea. Grades: ≥99% by HPLC. CAS No. 228544-65-8. Molecular formula: C25H27N3O3S. Mole weight: 449.57. | |
| Vulpinic acid | Vulpinic acid. Group: Biochemicals. Alternative Names: (a-E) -a- (3-Hydroxy-5-oxo-4-phenyl-2 (5H) -furanylidene) benzeneacetic Acid Methyl Ester. Grades: Highly Purified. CAS No. 521-52-8. Pack Sizes: 500mg, 1g, 2g, 5g, 10g. Molecular Formula: C19H14O5. US Biological Life Sciences. | Worldwide |
| VUN32779 | VUN32779, also known as 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one is a chemical reagent for research use. Uses: Designed for use in research and industrial production. Additional or Alternative Names: VUN32779; VUN 32779; VUN-32779. Product Category: Others. Appearance: Solid powder. CAS No. 1616632-77-9. Molecular formula: C24H26N4O. Mole weight: 386.5. Purity: >98%. IUPACName: 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one. Canonical SMILES: O=C1N(CC2=CC=CC=C2C)C3=NCCN3C4=C1CN(CC5=CC=CC=C5)CC4. Product ID: ACM1616632779. Alfa Chemistry ISO 9001:2015 Certified. |  |
| VUN73874 | VUN73874, also known as GOT1 inhibitor 2c, is a glutamate-oxaloacetate transaminase 1 (GOT1)? inhibitor. This compound was first reported in Bioorg Med Chem Lett. 2018 Sep 1;28(16):2675-2678. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GOT1 inhibitor 2c; VUN73874; VUN-73874; VUN 73874. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 732973-87-4. Molecular formula: C19H19ClN4O. Mole weight: 354.84. Purity: >98%. IUPACName: N-(4-Chlorophenyl)-4-(1H-indol-4-yl)piperazine-1-carboxamide. Canonical SMILES: O=C(N1CCN(C2=CC=CC3=C2C=CN3)CC1)NC4=CC=C(Cl)C=C4. Product ID: ACM732973874. Alfa Chemistry ISO 9001:2015 Certified. | |
| Vunakizumab | Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Anti-Human IL17A Recombinant Antibody. CAS No. 1792181-33-9. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99335. | |
| VUT-MK142 | VUT-MK142 is a potent new cardiomyogenic synthetic agent promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes, which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1313491-22-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-122610. | |
| VV116 | VV116, also known as JT001, is an oral drug candidate of nucleoside analog against SARS-CoV-2. VV116 is a deuterated, tri-isobutyrate ester prodrug of the RDV parent nucleoside, and is rapidly metabolized into the parent nucleoside (116-N1) in the body. 116-N1 is intracellularly converted to the nucleoside triphosphate active form, which would interfere with the function of RNA-dependent RNA polymerase of SARS-CoV-2, thus exerting antiviral effects (Fig. 1). VV116 showed potent activity against a panel of SARS-CoV-2 variants (alpha, beta, delta, and omicron) and excellent therapeutic efficacy in the mice model. Uses: Designed for use in research and industrial production. Additional or Alternative Names: VV116; VV 116; VV-116; JT001; JT-001; JT 001. Product Category: Others. Appearance: Solid powder. CAS No. 2647442-33-7. Molecular formula: C24H30DN5O7. Mole weight: 502.55. Purity: >98%. IUPACName: (2R,3R,4R,5R)-2-(4-amino-5-deuteropyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-cyano-5-((isobutyryloxy)methyl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate). Canonical SMILES: CC(C(OC[C@H]1O[C@](C#N)([C@@H]([C@@H]1OC(C(C)C)=O)OC(C(C)C)=O)C2=CC([2H])=C3N2N=CN=C3N)=O)C. Product ID: ACM2647442337. Alfa Chemistry ISO 9001:2015 Certified. | |
| Vv-AMP1 | Vv-AMP1 is an antibacterial peptide isolated from Vit is vinifera. It has activity against fungi. Synonyms: Arg-Thr-Cys-Glu-Ser-Gln-Ser-His-Arg-Phe-Lys-Gly-Thr-Cys-Val-Arg-Gln-Ser-Asn-Cys-Ala-Ala-Val-Cys-Gln-Thr-Glu-Gly-Phe-His-Gly-Gly-Asn-Cys-Arg-Gly-Phe-Arg-Arg-Arg-Cys-Phe-Cys-Thr-Lys-His-Cys. Molecular formula: C216H343N81O64S8. Mole weight: 5355.08. | |
| VX-11e | VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK, which is extracellular signal-regulated kinases. It is an antitumor agent and potently blocks proliferation of HT29 cells. Synonyms: VX-11e; VX 11e; VX11e; VTX-11e; VTX11e; VTX 11e; ERK-11e; ERK 11e; ERK11e. Grades: >98%. CAS No. 896720-20-0. Molecular formula: C24H20Cl2FN5O2. Mole weight: 500.35. | |
| VX-148 | VX-148 is a novel, uncompetitive IMPDH inhibitor with a K(I) value of 6 nM against IMPDH type II enzyme. VX-148 is slightly more potent than mycophenolic acid and VX-497 in inhibiting the proliferation of mitogen-stimulated primary human lymphocytes (IC(50) value of ~80 nM). VX-148 does not inhibit proliferation of nonlymphoid cell types such as fibroblasts, indicating selectivity for inhibition of IMPDH activity. VX-148 significantly prolongs skin graft survival at 100 mg/kg b.i.d. in mice. Synonyms: VX148; VX 148; (R)-1-cyanobutan-2-yl ( (S) -1- (3- (3- (4-cyano-3-methoxyphenyl) ureido) phenyl) ethyl) carbamate. Grades: 98%. CAS No. 297730-05-3. Molecular formula: C23H25N5O4. Mole weight: 435.48. | |
| VX-150 | VX-150 is a NaV1.8 blocker that is currently in phase II clinical trial for the treatment of patients with acute pain. Study shows that VX-150 significantly alleviates postoperative pain. Synonyms: Benzamide, N-[1,2-dihydro-2-oxo-1-[(phosphonooxy)methyl]-4-pyridinyl]-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)-; N-[1,2-Dihydro-2-oxo-1-[(phosphonooxy)methyl]-4-pyridinyl]-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide; VX 150; VX150; (4-(2-(4-Fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate. Grades: ≥95%. CAS No. 1793080-72-4. Molecular formula: C21H17F4N2O7P. Mole weight: 516.33. | |
| VX-166 | VX-166 is a caspase inhibitor and can be used as a novel potential treatment for sepsis. VX-166 can also reduce fibrosis in an animal model of nonalcoholic steatohepatitis. Uses: Sepsis. Synonyms: VX166, VX 166, VX-166; (S)-3-((S)-2-(3-((methoxycarbonyl)amino)-2-oxopyridin-1(2H)-yl)butanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid. Grades: 98%. CAS No. 800408-39-3. Molecular formula: C22H21F4N3O8. Mole weight: 531.41. | |
| VX-222 (VCH-222, Lomibuvir) | VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2. Synonyms: 2-Thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[(cis-4-hydroxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-; 5-(3,3-Dimethyl-1-butyn-1-yl)-3-[(cis-4-hydroxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-2-thiophenecarboxylic acid; Lomibuvir; VCH 222; VX 222; VX222. Grades: >98%. CAS No. 1026785-59-0. Molecular formula: C25H35NO4S. Mole weight: 445.61. | |
| VX-661 | VX-661 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used in combination with Ivacaftor in the treatment of cystic fibrosis. Synonyms: 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]cyclopropanecarboxamide; VX 661; VX661; Tezacaftor. Grades: 98%. CAS No. 1152311-62-0. Molecular formula: C26H27F3N2O6. Mole weight: 520.50. | |
| VX 702 | VX 702. Group: Biochemicals. Grades: Purified. CAS No. 479543-46-9. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| VX-702 | VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38&beta. Synonyms: VX-702; VX 702; VX702. Grades: >98%. CAS No. 745833-23-2. Molecular formula: C19H12F4N4O2. Mole weight: 404.3. | |
| VX-702 | VX-702. Group: Biochemicals. Alternative Names: 6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide. Grades: Highly Purified. CAS No. 745833-23-2. Pack Sizes: 2mg, 5mg, 10mg, 25mg, 50mg. Molecular Formula: C19H12F4N4O2. US Biological Life Sciences. | Worldwide |
| VX 745 | VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome. Group: Biochemicals. Alternative Names: 5-(2,6-Dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-6H-pyrimido[1,6-b]pyridazin-6-one. Grades: Highly Purified. CAS No. 209410-46-8. Pack Sizes: 25mg. US Biological Life Sciences. | Worldwide |
| VX-745 | VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome. Synonyms: VX-745; VX 745; VX745; VRT-031745, VD-31745; VRT 031745, VD 31745; VRT031745, VD31745; Neflamapimod. Grades: 0.97. CAS No. 209410-46-8. Molecular formula: C19H9Cl2F2N3OS. Mole weight: 436.258. | |
| VX-765 | VX-765. Group: Biochemicals. Alternative Names: N-(4-Amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]-L-prolinamide; Belnacasan. Grades: Highly Purified. CAS No. 273404-37-8. Pack Sizes: 5mg. Molecular Formula: C24H33ClN4O6, Molecular Weight: 509. US Biological Life Sciences. | Worldwide |
| VX-787 | VX-787, a pyrrolopyridine derivative, has been found to be an antiviral agent and is still under Phase II trial against Influenza A virus infection. Synonyms: VX-787; VX 787; VX787; JNJ-872; JNJ 872; JNJ872; VRT-0928787; VRT 0928787; VRT0928787;pimodivir; (2S,3S)-3-((5-Fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)bicyclo[2.2.2]octane-2-carboxylic Acid. Grades: 98%. CAS No. 1629869-44-8. Molecular formula: C20H19F2N5O2. Mole weight: 399.40. | |
| VX-809 (Lumacaftor) | VX-809 (Lumacaftor). Group: Biochemicals. Alternative Names: 3- [6- [ [ [1- (2, 2-Difluoro-1, 3-benzodioxol-5-yl) cyclopropyl] carbonyl] amino] -3-methyl-2-pyridinyl] benzoic Acid; Lumacaftor; VRT 826809. Grades: Highly Purified. CAS No. 936727-05-8. Pack Sizes: 50mg, 100mg, 250mg. Molecular Formula: C??H??F?N?O?, Molecular Weight: 452.51. US Biological Life Sciences. | Worldwide |
| VY-3-135 | VY-3-135 is a potent ACSS2 inhibitor. VY-3-135 acts as a transition-state mimetic to block ACSS2 activity in vitro and in vivo. Pharmacologic inhibition of ACSS2 as a single agent impaired breast tumor growth. The aqueous solubility of VY-3-135 was 21.7 μM. The aqueous solubility of VY-3-135 was 21.7 μM. VY-3-135 is a potent low nanomolar inhibitor of ACSS2 in cancer cells in vitro. VY-3-135 potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors. Uses: Designed for use in research and industrial production. Additional or Alternative Names: VY-3-135; VY3-135; VY 3-135; VY-3135; VY3135; VY 3135. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1824637-41-3. Molecular formula: C26H27N3O3. Mole weight: 429.52. Purity: >98%. IUPACName: (R)-1-Ethyl-2-(hydroxydiphenylmethyl)-N-(2-hydroxypropyl)-1H-benzo[d]imidazole-6-carboxamide. Canonical SMILES: O=C(C1=CC=C2C(N(CC)C(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)=N2)=C1)NC[C@H](O)C. Product ID: ACM1824637413. Alfa Chemistry ISO 9001:2015 Certified. | |
| VZHE-039 | VZHE-039 is a structurally-enhanced allosteric hemoglobin effector. Study in vitro showed that VZHE-039 inhibited sickling of SS erythrocytes in a dose-dependent manner. The result of in vivo studies showed that AUCtrap increased supra-proportionally with dose after I.P. administration; the limited sampling schedule suggested an I.P. bioavailability of >20%. VZHE-039 is promisingly to be a novel anti-sickling drug. Uses: Potential anti-sickling drug. Synonyms: VZHE-039; VZHE039. | |
Our database is helping our users find suppliers everyday.
